Melanoma, a malignancy of pigment-producing melanocytes, is notorious for its potential to metastasize early through lymphatic pathways. The identification of nodal metastatic involvement remains a cornerstone in staging and guiding therapeutic decisions. Currently, sentinel lymph node biopsy—a procedure in which the first draining lymph node(s) from a tumor site is surgically removed and analyzed—serves as the gold standard for evaluating nodal status. However, this procedure, although minimally invasive compared to full lymphadenectomy, still carries risks such as surgical complications, lymphedema, and anesthesia-related effects, highlighting the clinical imperative to refine patient selection for SLNB.

The MERLIN_001 trial, spearheaded by Dr. Vernon Sondak of Moffitt Cancer Center, leveraged a clinicopathologic gene expression profile test that uniquely synthesizes molecular gene expression patterns with key clinical data, including age and tumor thickness. This nuanced profile enhances risk stratification by categorizing patients into low- or high-risk groups for sentinel lymph node metastasis with superior accuracy compared to traditional clinical parameters alone. By assessing expression signatures alongside tumor mitotic rate and histologic subtype, this test offers a multifaceted biomarker platform that captures the tumor’s molecular aggressiveness and clinical behavior.

Crucially, the blinded, prospective nature of the study—which analyzed data from over 1,700 early-stage melanoma patients—affirms the robustness and reproducibility of the test. Participants with T1b to T3b melanomas and select high-risk T1a lesions were enrolled between 2021 and 2024. All patients underwent standard sentinel lymph node biopsy independent of gene expression results, ensuring unbiased assessment of the assay’s predictive power. Importantly, neither patients nor clinicians had access to test outcomes at the time of treatment, preserving the trial’s integrity in evaluating true predictive accuracy.

The trial’s results reveal that the gene expression profile test classified 37% of participants as low risk for nodal metastasis, with an impressively low sentinel node positivity rate of only 7.1% within this group. In stark contrast, the high-risk group exhibited a substantially elevated positivity rate of 23.8%. The negative predictive value—a measure indicating the probability that patients classified as low risk truly do not have nodal involvement—reached 92.9%, underscoring the test’s reliability in ruling out occult nodal disease. Such a high negative predictive value suggests that a significant subset of patients might safely omit SLNB without compromising oncologic outcomes.

An additional salient finding is the assay’s consistent performance across diverse melanoma subtypes, anatomical tumor sites, and age brackets, including patients aged 65 and older. Notably, nearly half of elderly patients were classified as low risk, with only a 6.6% sentinel node positivity rate, indicating that the test could have particular utility in populations where surgical morbidity is often a greater concern. This stratification capability augments personalized medicine efforts, guiding nuanced surgical decisions that balance disease control with quality of life considerations.

From a clinical management perspective, sentinel lymph node status heavily influences subsequent treatment algorithms, including indications for adjuvant immunotherapy and tailored surveillance protocols. By reliably identifying patients at low risk for nodal involvement, the gene expression profile test stands to reduce the frequency of unnecessary SLNB procedures that contribute to healthcare costs, patient anxiety, and procedural complications. This aligns with a broader movement towards de-escalation of overtreatment in oncology when safe and feasible.

Dr. Jonathan Zager, a surgical oncologist contributing to the study, highlighted the trial’s transformative potential: integrating molecular diagnostics with clinical judgement equips physicians with an evidence-based tool to optimize care pathways. The Merlin assay’s ability to discern truly low-risk individuals enables clinicians to contemplate foregoing SLNB—and thus general anesthesia—for many patients, an advancement with considerable implications for patient safety and resource utilization.

This study builds upon prior smaller retrospective and prospective analyses, which suggested that gene expression profiling could supplement risk assessment in melanoma. The MERLIN_001 trial’s large sample size and prospective design provide the highest level of evidence to date supporting the clinical application of molecular classifiers in determining sentinel node status. These findings may invigorate guideline discussions and reshape recommendations surrounding SLNB candidacy.

The gene expression profile test combines the analysis of expression levels of multiple genes implicated in melanoma progression and metastatic potential, integrating this molecular signature with established clinical factors via sophisticated algorithms. This holistic approach capitalizes on the pathobiological heterogeneity of melanoma, surpassing the predictive limitations of conventional staging metrics. Incorporating such precision tools represents a paradigm shift from population-based guidelines to individual-centric decision-making.

As this assay gains traction and adoption in clinical practice, ongoing research will be critical to monitoring long-term outcomes, validating the reproducibility of findings across broader populations, and evaluating cost-effectiveness. Meanwhile, the promise of refining the melanoma treatment landscape through minimally invasive, molecularly guided strategies offers hope for improved patient experiences and outcomes.

Moffitt Cancer Center, a nationally recognized Comprehensive Cancer Center, serves as a hub for innovative oncology research and multidisciplinary care delivery. The MERLIN_001 trial exemplifies collaborative efforts leveraging cutting-edge molecular science to translate research breakthroughs into tangible clinical benefits, advancing toward Moffitt’s mission to prevent and cure cancer.

This landmark trial signifies a momentous step in melanoma research, demonstrating how the confluence of genomics and clinical oncology can transform surgical decision-making. With the capacity to accurately predict nodal metastasis risk, the gene expression profile test stands poised to redefine standards of care, optimize therapeutic strategies, and ultimately improve the lives of countless melanoma patients worldwide.

Subject of Research: People

Article Title: Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status

News Publication Date: 22-Oct-2025

Web References:

• JAMA Surgery Article
• Moffitt Cancer Center
• National Cancer Institute-designated Comprehensive Cancer Centers

References:
10.1001/jamasurg.2025.4399

Keywords: Cancer research

Melanoma, recognized as the deadliest form of skin cancer, poses significant challenges in early detection and precise staging. Traditional methods necessitate sentinel lymph node biopsy—a surgical procedure requiring general anesthesia—where several lymph nodes are excised and examined histologically for metastatic deposits. Despite its diagnostic value, this surgery is associated with potential complications such as infection, lymphedema, and prolonged recovery, while approximately 80% of these biopsies reveal no cancerous involvement, underscoring the critical need for less invasive yet accurate diagnostic tools.

The innovative Merlin CP-GEP Test—which stands for Clinical-Pathologic Gene Expression Profile—employs a sophisticated algorithm that integrates genomic data derived from eight specific gene expression markers within the melanoma tumor tissue alongside critical clinical parameters like patient age and tumor thickness, measured in millimeters. This amalgamation of molecular and clinical data forms a robust predictive model that estimates the probability of lymphatic metastasis with remarkable accuracy. Uniquely, the test utilizes tumor samples obtained during the initial diagnostic biopsy, eliminating the necessity for additional invasive procedures.

A multicenter prospective clinical trial encompassing 1,761 melanoma patients from nine major U.S. cancer institutions over three years validated the test’s clinical utility. Astonishingly, the test demonstrated that around 93% of individuals classified as low-risk for nodal metastasis truly had no cancer in their lymph nodes. Conversely, approximately 25% of patients identified as high-risk did harbor lymph node involvement. These findings signify an unprecedented stride toward personalized oncologic care, allowing clinicians to tailor interventions grounded in each tumor’s genomic blueprint.

Dr. Tina Hieken, the study’s lead author and a surgical oncologist at the Mayo Clinic Comprehensive Cancer Center, emphasized the transformative potential of this test, stating that its implementation could drastically reduce the necessity for sentinel lymph node biopsies without compromising patient outcomes. By harnessing the tumor’s intrinsic biological signals, clinicians can now stratify patients more precisely, prioritizing surgical interventions for those with demonstrable metastatic risk while alleviating low-risk patients from unnecessary operative morbidities.

Melanoma pathogenesis is complex, involving a cascade of molecular events that modulate tumor growth, invasion, and immune evasion. The Merlin CP-GEP Test capitalizes on this molecular intricacy by decoding the expression profiles of genes implicated in tumor aggressiveness and microenvironmental interactions. This level of nuanced insight transcends conventional histopathological assessments, facilitating a deeper understanding of each tumor’s metastatic potential.

The implications of this personalized approach extend beyond surgical decision-making. Accurate risk stratification is pivotal in determining the need for adjuvant therapies and surveillance strategies, thereby optimizing resource allocation and enhancing patient quality of life. Ongoing research aims to elucidate how integrating the test into routine clinical practice influences long-term outcomes, including recurrence rates and survival metrics.

Moreover, the success of this genomic assay reflects a broader paradigm shift in oncology toward precision medicine—where molecular diagnostics and bioinformatics converge to inform individualized care pathways. As researchers continue to unravel the genomic landscape of melanoma, such assays will likely become integral to multidisciplinary cancer management, heralding an era where treatment is increasingly tailored to the unique genetic and phenotypic profile of each patient’s malignancy.

The study underscores the essential role that cross-institutional collaborations play in accelerating translational research. By combining the expertise of surgical oncologists, dermatologists, molecular biologists, and bioinformaticians, the team has effectively bridged the gap between laboratory discoveries and clinical application. This collaborative model serves as a blueprint for future endeavors seeking to transform cancer care through innovative diagnostic technologies.

Importantly, this test aligns with the Mayo Clinic Comprehensive Cancer Center’s mission to develop pioneering, patient-centered approaches that improve cancer detection, prevention, and treatment. Designated by the National Cancer Institute, the center epitomizes a commitment to excellence in cancer research, exemplified through initiatives like the Merlin CP-GEP Test, which leverages scientific innovation to directly impact clinical practice.

While the sentinel lymph node biopsy remains a valuable tool, especially in complex cases, the advent of gene expression profiling presents a compelling alternative for many patients. This transition could markedly reduce the physical and psychological burden associated with surgery, offering a safer, more efficient path for melanoma staging.

As scientific inquiry continues, researchers anticipate that molecular diagnostics will expand to encompass other cancer types and stages, further refining the precision medicine toolkit. The Merlin CP-GEP Test stands as a testament to this promising trajectory, illuminating a future where cancer care is not only effective but also minimally invasive and inherently personalized.

For medical professionals and patients alike, this genomic test represents hope—offering more clarity, less uncertainty, and a significant step toward conquering melanoma with intelligence and compassion.

Subject of Research: Gene expression profiling to predict sentinel lymph node status in melanoma patients

Article Title: Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status

News Publication Date: 22-Oct-2025

Web References:

• Mayo Clinic Comprehensive Cancer Center: https://www.mayoclinic.org/departments-centers/mayo-clinic-cancer-center
• JAMA Surgery (Study Publication): https://jamanetwork.com/journals/jamasurgery/fullarticle/2840207
• National Cancer Institute: https://www.cancer.gov/

References:

• Hieken, T. J., et al. (2025). Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status. JAMA Surgery.

Keywords: melanoma, sentinel lymph node biopsy, genomic test, gene expression profile, cancer staging, precision medicine, oncology diagnostics, melanoma metastasis, Merlin CP-GEP Test, molecular biomarkers

The research team collected comprehensive data from 682 breast cancer patients diagnosed between 2014 and 2022 across four major hospitals in China. They compiled preoperative grayscale ultrasound (US), color Doppler flow imaging (CDFI), and contrast-enhanced ultrasound (CEUS) scans alongside critical clinical information. This rich dataset laid the groundwork for developing a multifaceted radiomics model aimed at detecting ALNM—a vital prognostic indicator that directly influences treatment decisions and survival outcomes in breast cancer patients.

Axillary lymph node involvement remains a pivotal determinant in breast cancer staging and therapy planning. Conventionally, detecting metastasis relies on invasive procedures like sentinel lymph node biopsy, often fraught with complications and patient burden. The advent of noninvasive radiomics models that extract quantitative imaging features from ultrasound modalities introduces a paradigm shift—enabling precise preoperative prediction and potentially reducing unnecessary surgical interventions.

Central to the study’s methodology was the application of Least Absolute Shrinkage and Selection Operator (LASSO) regression to distill a vast array of radiomic features embedded within ultrasound images. This statistical technique refined feature selection by eliminating redundancies and identifying those most predictive of ALNM. Subsequently, eight distinct machine learning algorithms were utilized to construct radiomics models drawing on US, CDFI, and CEUS datasets individually and in combination, providing a robust framework to evaluate predictive performance.

The results demonstrated that the combined US + CDFI + CEUS model significantly outperformed ultrasound-only assessments in predicting the presence and extent of metastatic axillary lymph nodes. Specifically, the integrated radiomics model achieved Areas Under the Curve (AUCs) of 0.88 in the training set and maintained strong predictive accuracy in both internal and external validation cohorts, with AUCs exceeding 0.75. These statistics underscore the reliability and generalizability of the approach across diverse clinical environments.

Beyond binary classification of lymph node status (N0 versus N+), the model adeptly distinguished between varying metastatic burdens—a crucial clinical nuance. It achieved high AUCs when differentiating patients with 1–2 positive nodes from those with three or more, highlighting its ability to stratify patients based on metastatic extent. This granularity facilitates more tailored therapeutic regimens, optimizing outcomes while minimizing overtreatment.

Importantly, the study also explored the prognostic implications of integrating radiomics with systemic immunoinflammatory markers, including platelet count and neutrophil-to-lymphocyte ratio (NLR). Such markers reflect tumor-host interactions and the underlying inflammatory milieu, which are increasingly recognized as key determinants of cancer progression. By combining the radiomic signature (Radscore) with these clinical biomarkers, the researchers developed a composite model predicting disease-free survival (DFS) with notable accuracy.

This composite clinical-radiomics model exhibited C-indices ranging from 0.73 to 0.80 across different cohorts, outperforming models based solely on clinical data. In external validations, it demonstrated superior AUCs for predicting 2-, 3-, and 5-year DFS outcomes compared to clinical models alone, with improvements reaching statistical significance. Such advances enable oncologists not only to forecast metastatic spread but also to anticipate patient prognosis, facilitating more informed counseling and individualized surveillance strategies.

The utility of the model was further bolstered by rigorous calibration and decision curve analyses, which confirmed its clinical applicability and net benefit. Good agreement between observed and predicted outcomes indicated that the model’s predictions closely mirrored real-world patient trajectories. Decision curve analysis demonstrated tangible clinical benefits over existing tools, suggesting that adopting this radiomics-based approach could enhance decision-making in breast cancer management.

At the core of the innovation lies the incorporation of contrast-enhanced ultrasound, which augments traditional imaging by highlighting microvascular perfusion characteristics within suspicious lesions and nodes. CEUS provides dynamic functional information beyond morphological assessment, enabling extraction of texture and intensity-based radiomic features deeply linked to tumor biology and metastatic potential. This multimodal imaging strategy thus enriches data granularity and model robustness.

The study’s multicenter design and large patient cohort contribute to the robustness and external validity of findings. Data partitioning ensured rigorous training, internal validation, and external validation phases, mitigating overfitting risks—a common pitfall in radiomics research. The diverse population sampled from geographically and institutionally distinct centers strengthens the generalizability of conclusions, paving the way for broader clinical adoption.

Nonetheless, the authors acknowledge that further prospective studies are warranted to validate the model’s performance in routine clinical workflows and to assess integration feasibility with existing diagnostic protocols. Future research may also explore combining ultrasound radiomics with genomic or molecular biomarkers, fostering an integrative oncology paradigm blending imaging phenotypes with biological insights.

Moreover, the technology holds promise for guiding neoadjuvant therapy decisions, surgical planning, and personalized follow-up schedules. By accurately delineating lymph node status preoperatively, the model may reduce the need for invasive biopsies, lowering patient morbidity and healthcare costs. Predicting prognosis through combined imaging and inflammatory markers offers a noninvasive avenue to identify high-risk patients who may benefit from intensified treatments.

This advancement epitomizes the transformative potential of artificial intelligence and machine learning in oncology, leveraging routinely acquired imaging data to extract clinically actionable insights. As ultrasound is widely available, radiation-free, and cost-effective, deploying enhanced radiomics models such as this could democratize access to precision diagnostics worldwide, especially in resource-limited settings.

The study epitomizes a confluence of medical imaging, computational analysis, and clinical oncology, showcasing how interdisciplinary efforts can unlock novel diagnostic and prognostic capabilities. By converting complex imaging data into predictive models that inform real-world treatment pathways, research like this accelerates the transition from traditional medicine to precision oncology.

In summary, the novel multimodal ultrasound radiomics model combining grayscale US, CDFI, and CEUS represents a formidable tool in the battle against breast cancer. It not only elevates the accuracy of axillary lymph node metastasis detection but also synergizes with immunoinflammatory biomarkers to enhance prognosis prediction. Such integrative models promise to optimize patient stratification, personalize therapy, and ultimately improve survival and quality of life for countless breast cancer patients worldwide.

As this technology matures and is incorporated into clinical practice, it may redefine breast cancer care pathways, reducing diagnostic uncertainties and empowering clinicians with nuanced risk assessments. The synergistic blend of advanced imaging, machine learning, and biological markers portends a new era of precision oncology where treatment decisions are increasingly guided by data-driven insights.

This landmark study stands as a testament to the potential of radiomics combined with immunology to revolutionize cancer prognostication. It paves the way for future endeavors harnessing artificial intelligence to unravel complex disease patterns from noninvasive imaging, transforming clinical oncology from reactive to proactive, and setting new standards in patient-centered care.

Subject of Research:
Prediction of axillary lymph node metastasis and prognosis in breast cancer using multimodal ultrasound radiomics combined with immunoinflammatory markers.

Article Title:
Contrast-enhanced ultrasound radiomics model for predicting axillary lymph node metastasis and prognosis in breast cancer: a multicenter study.

Article References:
Li, S.Y., Li, Y.M., Fang, Y.Q. et al. Contrast-enhanced ultrasound radiomics model for predicting axillary lymph node metastasis and prognosis in breast cancer: a multicenter study. BMC Cancer 25, 1315 (2025). https://doi.org/10.1186/s12885-025-14632-9

Image Credits: Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-14632-9